BeOne Medicines (ONC) Change in Receivables (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Change in Receivables data on file, last reported at $75.3 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 136.3% year-over-year to $75.3 million in Q1 2026; TTM through Mar 2026 was $208.4 million, a 25.92% decrease from a year earlier, with the FY2025 full-year figure at $165.0 million, down 49.93% from the prior year.
• Change in Receivables for Q1 2026 stood at $75.3 million, up from -$2.3 million in the prior quarter.
• Over the last five years, Change in Receivables for ONC reached as high as $136.5 million in Q1 2023 and fell as low as -$292.6 million in Q1 2022.
• Historically, Change in Receivables has averaged $26.7 million across 5 years, with a median of $31.9 million in 2025.
• Across the five-year window, Change in Receivables slumped 1336.7% in 2022 and surged 2156.77% in 2024, its largest moves.
• Year by year, Change in Receivables stood at -$19.4 million in 2022, then soared by 330.96% to $44.8 million in 2023, then soared by 180.61% to $125.7 million in 2024, then slumped by 101.86% to -$2.3 million in 2025, then soared by 3317.95% to $75.3 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $75.3 million in Q1 2026, -$2.3 million in Q4 2025, and $93.9 million in Q3 2025.